Dimerix Limited (ASX: DXB) has announced the successful completion of the fifth planned review by the Independent Data Monitoring Committee (IDMC) of its ACTION3 Phase 3 clinical trial. The trial is evaluating DMX-200, a late-stage clinical asset, for the treatment of Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease. The IDMC's review found no safety concerns and recommended that the trial continue as planned.
The IDMC's role is to assess study data for participant safety, study conduct, and progress, and to advise on continuation, modification, or termination of the trial. This review is consistent with good clinical practice and was pre-specified in the ACTION3 study protocol.
"This encouraging recommendation of the IDMC confirms the strong emerging safety profile of DMX-200 and suggests that DMX-200 does not add a burden of side effects to patients, compared to commonly used treatments such as high dose steroids and immunosuppressants," said Dr. David Fuller, Chief Medical Officer at Dimerix. He added, "DMX-200 represents a real hope for the many patients suffering from FSGS kidney disease who currently have limited treatment options."
The ACTION3 clinical trial includes oversight by an IDMC as well as provision for interim safety reviews. The successful completion of this fifth review reinforces the commitment to patient safety and the integrity of the study.
